As this special Pall supplement of BioProcess International issue goes to press, progress continues in the field of cell therapy research. The revival of cell (and gene) therapy has been driven by some positive achievements that have occurred over the past decade.
Cell therapy products differ in many ways from traditional small-molecular and biologic products. The main difference is that, contrary to traditional biopharmaceutical applications in which cells secrete the product of interest, in cell therapy applications cells are the product. That brings a multitude of challenges as manufacturers navigate the industrialization pathway to determine an optimal manufacturing strategy for their therapy.
Read the full text of this article in the PDF (Login required).